Alendronate is the most popular bisphosphonate used to prevent osteoporotic fragility fractures in postmenopausal women.
INTRODUCTION
Osteoporosis is a major public health problem with a significant economic burden on the society (1) (2) (3) (4) . The main clinical manifestations of osteoporosis are low-energy fractures of the proximal femur, vertebrae, and distal radius. Nearly two million osteoporotic fractures occur annually in the United States at an estimated cost of more than $17 billion (5, 6) . Subtrochanteric and diaphyseal areas are considered to be the strongest parts of femur subjected to the highest stresses of the body (7) . The strongest bone of the body, femur diaphysis, is an unusual site for fracture due to minor trauma, and raises significant suspicion regarding the pathogenesis of the fracture. In recent years, some cases of subtrochanteric and diaphyseal fractures due to minor trauma have been reported in association with long-term alendronate therapy (8) (9) (10) . This pattern of fracture is defined as alendronate-induced atypical fracture. This study presents a case of bilateral femoral insufficiency fracture in a woman receiving long-term alendronate therapy.
CASE REPORT
While being treated in the Physical Therapy and Rehabilitation clinic for low back pain (lumbar degenerative disease and sciatica), a 65-year-old female fell in the hallway and suffered from right femoral midshaft pain and deformity. Radiography revealed a one-third distal femoral shaft fracture (Figure 1 ). Skeletal traction was applied from tuberositas tibia, and the patient was taken to the Orthopedics and Traumatology service for surgery. The patient's history showed that she had been using alendronate sodium for 5 years and she had pain for 3 months in both femurs. Radiographs taken a day before the fracture ( Figure 2 ) revealed a nondisplaced bilateral femoral shaft fracture that was misdiagnosed by the physician. The patient was operated in the lateral decubitus position under a nonradiolucent operating reduction of the right femur was performed, and it was internally fixed with trochanteric entry intramedullary nail (Tasarım Med, Medical Device Company A.S., Turkey) ( Figure 3 ). The option of prophylactic nailing of the nondisplaced fracture of the left femur was offered, but the patient refused. Postoperative alendronate therapy was stopped, and strontium ranelate treatment was started because of the osteoporosis that was detected during the patient's bone mineral density (BMD) examination. Because of the left femoral insufficiency fracture, which the patient refused to get operated, no weight-bearing exercises were allowed for 6 weeks. After 6 weeks, the patient was started on weight-bearing exercises with two crutches. So, both operated and nonoperated femoral fractures healed well. At the postoperative 10th month, both femurs totally healed (Figures 4 and 5) . The outcomes of the fractures were radiographically and functionally perfect. The patient had no problem in both lower extremities.
DISCUSSION
MiThe diagnosis of alendronate-induced atypical or insufficiency fracture is concluded by a high index of clinical suspicion and confirmed by the typical radiological finding. The clinical presentation includes long-term bisphosphonate (alendronate) therapy (usually more than 5 to 7 years) and spontaneous fracture or fracture after minor trauma that may be followed by prodromal pain for few weeks in a relatively young postmenopausal woman. Sometimes the fracture occurs on both sides at the same time or in a short span of time. A lot of fragility fractures associated with biphosphonate treatment have been reported (Table 1 ) (9, (13) (14) (15) (16) (17) (18) . The typical radiographic image can be in the form of a transverse or short oblique fracture in the subtrochanteric or diaphyseal area of the femur, medial spiking of distal fragment, lateral cortical thickening, and identical bilateral involvement (15) (16) . Pathogenesis is explained by the strong antiosteoclastic activity of alendronate, which produces a severely suppressed bone turnover (SSBT) status but does not inhibit mineralization, which in turn produces a hypermineralized brittle bone (9-11). Microcracks, which result from stress and strain on bone due to daily activities, develop relatively more in a hypermineralized bone, and due to SSBT, these microcracks do not heal. So, they accumulate and ultimately produce a stress zone (7) . When this stress zone becomes weak enough to bear the body weight, the bone fractures spontaneously or with minor trauma. Alendronate, which is available since 1995, has a better patient compliance compared with other bisphosphonates available on the market owing to its weekly doses and better gastrointestinal tolerability. It is reasonable to assume that a huge number of people have been taking this drug for decades, but the reported incidence of this clinical condition is less in comparison to the assumed consumption (8) . The reason behind this may be the unawareness of some of the medical practitioners about this new clinical entity bacause of which many cases could not be diagnosed. The incidences of this fracture do not outweight the benefits of bisphosphonates in reducing osteoporosis-induced fracture. Therefore, it is not justifiable to stop prescribing bisphosphonate for the treatment of osteoporosis. Even radiographic surveillance of all the patients who have been using bisphosphonates for a long time is not economically feasible.
As in the present case, some patients may refuse to get operated for the nondisplaced insufficiency fractures prophylactically. In this scenario, biphosphonate treatment should be stopped, if needed other osteoporosis drugs (such as stronsium ranelate) 
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should be started, and the patient should be advised to not bear weight on the affected side for at least 6 weeks. After 6 weeks, the patient's thigh pain on the nondisplaced side resolved and during the clinical follow-ups, no problems were reported by the patient.
CONCLUSION
Despite the great success achieved by using biphosphanates (mainly alendronate) in osteoporotic patients during the last two decades, a group of patients may develop femoral fragility fractures secondary to SSBT caused by prolonged usage. The number of these cases are still relatively small but will probably increase in the future owing to the large number of patients treated with these drugs. It is therefore important to reserve continuation of biphosphonate therapy for more than 5 years for selected cases. Furthermore, clinicians should be aware of the association between long-term biphosphonate therapy and femoral fragility fractures. In patients with early changes, such as prodromal hip/thigh pain and lateral cortical thickness, stopping biphosphonate therapy and prophylactic nailing should be considered. It may be better to stop these medications after the patient achieves normal BMD.
